[Intravenous immunoglobulin in combined therapy for children with juvenile rheumatoid arthritis (evaluation of therapeutical efficiency and factors that influence them)].

The study was based on the follow-up of 20 patients with systemic juvenile rheumatoid arthritis who received intravenous immunoglobulin. The study comparatively analyzed the efficiency of the therapy alone and in combination with steroids. The immunoglobulin was shown to have positive effects on both articular and extraarticular manifestations of the disease particularly in a group of children untreated with corticosteroids.

Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis.

Results from three randomized placebo-controlled trials were combined in a meta-analysis to compare the clinical utility of four advanced drug therapy agents used to treat juvenile rheumatoid arthritis (JRA): D-penicillamine (10 mg/kg/d), hydroxychloroquine (6 mg/kg/d), auranofin (oral gold, 0.15 to 0.20 mg/kg/d), and two low dose levels of methotrexate [5MTX, 5 mg/M2/wk; 10MTX, 10 mg/M2/wk].

Chlamydial associated syndrome of arthritis and eye involvement in young children.

The current classification of juvenile rheumatoid arthritis (JRA) consists of several distinct subsets. We describe 6 children (2 boys, 4 girls, mean age 3.7 years, range 2.